ArticleApplied health economics and health policy2025

Exploratory Cost-Utility Analysis of a 37-Gene Panel Versus Usual Care to Guide Therapy for Patients with Intermediate-Risk Myeloid Malignancies.

Daniel Lindsay et al.PubMed ↗Publisher ↗

No numbers read from the abstract.